Propanc Biopharma (NASDAQ Uplisting)

General Information
Business:	Note: This is NOT an IPO. This is a NASDAQ Uplisting from the OTC Pink Marketplace, where the stock trades under the symbol “PPCB”. This is also a unit offering. Each unit consists of one share of common stock and one warrant to buy one share of common stock. (Incorporated in Delaware) We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes. Note: Net loss and revenue figures are for the fiscal year that ended June 30, 2024. (Note: Propanc Biopharma is offering 1.0 million shares at a price range of $4.00 to $6.00 to raise $5.0 million, if priced at the $5.00 mid-point of its range, according to its S-1/A filing dated March 28, 2025.)
Industry:	Pharmaceuticals
Employees:	2
Founded:	2007
Contact Information
Address	302, 6 Butler Street Camberwell, VIC 3124 Australia
Phone Number	+61 03 9882 0780
Web Address	https://www.propanc.com/
View Prospectus:	Propanc Biopharma (NASDAQ Uplisting)
Financial Information
Market Cap	$65.56mil
Revenues	$0 mil (last 12 months)
Net Income	$-2.01 mil (last 12 months)
IPO Profile
Symbol	PPCB
Exchange	NASDAQ
Shares (millions):	1.0
Price range	$4.00 - $6.00
Est. $ Volume	$5.0 mil
Manager / Joint Managers	D. Boral Capital (ex-EF Hutton)/Craft Capital
CO-Managers
Expected To Trade:	4/7/2025
Day:	Week of
Quiet Period Expiration Date:	Available only to Subscribers
Lock-Up Period Expiration Date:	Available only to Subscribers
SCOOP Rating	Available only to Subscribers
Rating Change	Available only to Subscribers

Propanc Biopharma (NASDAQ Uplisting)

Note: This is NOT an IPO. This is a NASDAQ Uplisting from the OTC Pink Marketplace, where the stock trades under the symbol “PPCB”. This is also a unit offering. Each unit consists of one share of common stock and one warrant to buy one share of common stock.

(Incorporated in Delaware)

Note: Net loss and revenue figures are for the fiscal year that ended June 30, 2024.

(Note: Propanc Biopharma is offering 1.0 million shares at a price range of $4.00 to $6.00 to raise $5.0 million, if priced at the $5.00 mid-point of its range, according to its S-1/A filing dated March 28, 2025.)